Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preliminary results from PRIMARY2: bringing colour to a grey arena.

The Lancet. Oncology·2026
Same author

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression.

Prostate cancer and prostatic diseases·2026
Same author

Characterizing the Activity of Inflammasome-Related Genes and Their Association With Oncological Outcomes in Prostate Cancer.

The Prostate·2026
Same author

Elective Nodal Radiation Therapy in Localized Prostate Cancer: A Meta-Analysis.

International journal of radiation oncology, biology, physics·2026
Same author

NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Patient-reported distress and anxiety during cone-beam CT imaging sessions with increased gantry rotation speeds.

Technical innovations & patient support in radiation oncology·2026
Same journal

Role and relevance of genetic testing in patients with kidney stones: a review from EAU Section of Endourology.

Current opinion in urology·2026
Same journal

Advances in evaluating and delivering nontechnical skills training: The use of simulation, robotics, artificial intelligence and virtual reality.

Current opinion in urology·2026
Same journal

Educating for a sustainable future: faculty and student perspectives and a review of environmental sustainability in medical education - an EAU endourology study.

Current opinion in urology·2026
Same journal

Shaping the future of endourology: role of education, simulation and uro-technology: a scoping review by the EAU Section of Endourology.

Current opinion in urology·2026
Same journal

A review of emerging technologies and techniques for percutaneous nephrolithotomy access.

Current opinion in urology·2026
Same journal

Artificial intelligence in kidney cancer: a review of clinical applications across the disease spectrum.

Current opinion in urology·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

Tissue-based genomics: which test and when.

Randy A Vince1, Jeffrey J Tosoian1, William C Jackson2

  • 1Department of Urology.

Current Opinion in Urology
|October 5, 2019
PubMed
Summary
This summary is machine-generated.

Genomic tests offer new insights into prostate cancer biology, aiding treatment decisions. These tissue-based assays provide prognostic information beyond traditional factors for localized prostate cancer.

More Related Videos

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Related Experiment Videos

Last Updated: Jan 6, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.7K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K

Area of Science:

  • Oncology
  • Genomics
  • Urology

Background:

  • Prostate cancer"s clinical course is highly variable, from indolent to aggressive.
  • Traditional risk factors (PSA, stage, Gleason score) have limitations in predicting tumor biology.
  • Tissue-based genomic tests are emerging to better characterize prostate cancer.

Purpose of the Study:

  • To review the clinical utility of genomic assays in prostate cancer management.
  • To focus on three critical scenarios: active surveillance vs. definitive therapy, adjuvant radiation, and concurrent therapies.

Main Methods:

  • Review of current literature on tissue-based genomic assays for prostate cancer.
  • Analysis of data regarding the prognostic value of genomic tests.

Main Results:

  • Genomic tests provide prognostic information independent of traditional risk factors.
  • These assays can augment clinical decision-making for localized prostate cancer.
  • Specific applications include guiding active surveillance, adjuvant radiation, and concurrent therapies.

Conclusions:

  • Commercially available genomic tests show promise in refining prostate cancer management.
  • Further data will clarify the optimal use of these tests in various clinical scenarios.